Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M

Xeris Biopharma Holdings, Inc.

2025-Q1 EPS reported -$0.06 revenue$60,119,000

Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.
Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).
Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.
FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.
Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.